Chronic Pain Clinical Trial
— MORPHOOfficial title:
Managing Opioid Related Sleep Apnea With Acetazolamide
Patients with chronic pain who use opioids appear to be at increased risk for breathing issues during sleep, termed sleep disordered breathing (SDB). Treatment of SDB often consists of use of a device during sleep that provides continuous positive airway pressure (CPAP) via a mask interface. However, this device is not effective or tolerated in all individuals. The goal of this study is to examine whether a medication called acetazolamide can improve SDB, as an alternative to CPAP treatment. The investigators will measure the improvement in SDB, as well as any change in symptoms, during a 1 week treatment with acetazolamide compared with 1 week of placebo (sugar pill). This study will help to provide data for longer term studies of treatment for SDB in patients who use opioids.
Status | Recruiting |
Enrollment | 34 |
Est. completion date | June 1, 2025 |
Est. primary completion date | April 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age 18+ - Chronic pain - Chronic opioid use (daily use for >3 months duration) with >/= 20 oral Morphine Equivalent Dose (MEqD) per day - Apnea-hypopnea index >/= 10 events/hr (hypopnea definition: = 3% desaturation or arousal criteria per American Academy of Sleep Medicine 2012 scoring rules) Exclusion Criteria: - Use of opioids outside medical supervision (e.g. recreational use) - Unable or unwilling to withhold any ongoing SDB treatment (e.g. CPAP) for the duration of the study - Urgent need to initiate effective SDB therapy - Chronic lung disease (other than well-controlled asthma) - Active cardiac disease including heart failure, chest pain, or heart rhythm problems - Neurological or developmental problems affecting breathing - Major sleep disorders other than sleep apnea - Chronic kidney disease - Cirrhosis of the liver - Active cancer treatment or limited life expectancy - Psychiatric disease other than controlled mood disorders - Use of diuretics, potassium supplementation, or medications that may affect potassium - Allergy to study drug or related compounds including sulfa drugs - Know electrolyte disturbances - Hospitalized in the last 90 days or anticipated hospitalization within 3 months - Alcohol use >2 standard drinks per day - Presence of tracheostomy or artificial airway - Prisoners - Pregnancy or anticipating pregnancy in next 2 months, or nursing - Unable or unwilling to provide informed consent - Unable to follow study protocol |
Country | Name | City | State |
---|---|---|---|
United States | University of California San Diego | San Diego | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Diego | National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance | Higher scores indicate more symptoms | 1 week | |
Other | Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Related Impairment | Higher scores indicate more symptoms | 1 week | |
Other | Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Behavior | Higher scores indicate more symptoms | 1 week | |
Other | Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference | Higher scores indicate more symptoms | 1 week | |
Other | 10 minute psychomotor vigilance test | Total lapses and mean reaction time | 1 week | |
Primary | Apnea-hypopnea index, NREM Supine | The AHI is a measure of sleep apnea severity and is defined as the number of apneas (no breathing for 10+ seconds) and hypopneas (reduced breathing for 10+ seconds associated with a >=3% desaturation or cortical arousal) per hour of sleep. For the primary outcome, the study will evaluate the AHI during non-rapid eye movement sleep in the supine position. | 1 week | |
Secondary | Apnea-hypopnea index, Total | The AHI is a measure of sleep apnea severity and is defined as the number of apneas (no breathing for 10+ seconds) and hypopneas (reduced breathing for 10+ seconds associated with a >=3% desaturation or cortical arousal) per hour of sleep. For the primary outcome, the study will evaluate the AHI during sleep in supine and lateral position. | 1 week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|